Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
908 Devices Inc. develops purpose-built handheld chemical analysis devices for point-of-need use in health, safety and defense technology applications. Its news centers on Mass Spec and FTIR product activity, installed-device growth, recurring revenue, and applications such as narcotics identification, toxic exposure screening and security-threat analysis.
Company updates also cover acquisitions and portfolio expansion, including the completed purchase of NIRLAB AG and its AI-powered, cloud-connected near-infrared spectroscopy platform for narcotics screening. Other recurring items include quarterly financial results, revenue outlooks, executive and strategy appointments, funded partnership revenue, and investor conference participation.
908 Devices (Nasdaq: MASS) announced that its management will present at the 32nd Annual Gabelli Aerospace & Defense Symposium/b) on , in New York City. The presentation is scheduled for 3:45 p.m. Eastern Time and will be accessible via webcast through the conference host’s website, with an archived version available about one week later on 908 Devices’ investor relations website.
908 Devices (Nasdaq: MASS) announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 17th Annual Midwest IDEAS Conference on Wednesday, August 26, 2026. The company presentation is scheduled for 9:55 a.m. CT / 10:55 a.m. ET and will be available via webcast through the conference host’s website and the investor relations section of the 908 Devices website.
908 Devices (Nasdaq: MASS) reported second quarter 2026 revenue of $16.1 million, up 23% year-over-year, with recurring revenue of $4.9 million (31% of total) and installed base up 23% to 4,101 devices. GAAP gross margin was 52%, and adjusted gross margin was 57%, about 85 basis points higher than a year ago.
Net loss from continuing operations was $11.9 million, while Adjusted EBITDA loss narrowed to $1.9 million, more than 50% lower year-over-year. Cash, cash equivalents and marketable securities were $101.5 million with no debt. The company raised its 2026 revenue outlook to $68–70 million, implying 21–25% growth, and highlighted a post‑quarter $6 million ProtectIR order.
908 Devices (Nasdaq: MASS) announced its participation in the Canaccord Genuity 46th Annual Growth Conference. Company management is scheduled to present on Wednesday, August 12 at 12:30 p.m. Eastern Time. A live and archived webcast of the presentation will be available in the Investors section of the company website.
908 Devices (Nasdaq: MASS) will report its second quarter 2026 financial results before the market opens on Tuesday, August 11, 2026. Company management will host a webcast conference call at 8:30 a.m. Eastern Time, with live audio and a replay available via the Investors section of the company website.
908 Devices (Nasdaq:MASS) granted inducement stock options to four new non-executive employees under its 2026 Inducement Plan, effective June 1, 2026. The awards cover an aggregate 179,912 shares with an exercise price of $8.63, matching the June 1, 2026 closing price.
Options vest over four years: 25% after one year, then 36 equal monthly installments for the remaining 75%, subject to continued service, and were approved under Nasdaq Listing Rule 5635(c)(4).
908 Devices (Nasdaq: MASS) announced that CEO Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 16th Annual East Coast IDEAS Investor Conference on June 10, 2026, at 8:35 a.m. ET.
The presentation will be webcast via the conference website and the 908 Devices investor relations page.
908 Devices (Nasdaq: MASS) reported Q1 2026 revenue of $13.4 million, up 14% year-over-year, with recurring revenue of $4.0 million (30% of total). Adjusted gross margin rose to 57% (290 bps improvement). Installed base grew 23% to 3,903 devices. Cash was $111.7 million with no debt. The company acquired NIRLAB AG after quarter end and raised 2026 revenue guidance to $67.0M–$70.0M (19%–25% growth).
908 Devices (Nasdaq: MASS) has completed the acquisition of NIRLAB AG, a Lausanne-based developer of AI-powered, cloud-connected near-infrared (NIR) spectroscopy for handheld narcotics screening. The deal includes $15 million upfront consideration ($13M cash, $2M stock) and up to $8 million in additional 908 Devices common stock tied to milestones over 20 months.
NIRLAB’s handheld analyzes >400 drugs, quantifies purity and THC/CBD, and is proven with over 1,000,000 field analyses; the company employs 15 people and was founded in 2021 as a University of Lausanne spin-out. A conference call/webcast on Q1 2026 results is scheduled May 6, 2026 at 8:30 AM ET.
908 Devices (Nasdaq: MASS) will report first quarter 2026 financial results before market open on Wednesday, May 6, 2026.
Management will host a live webcast and conference call beginning at 8:30 a.m. Eastern Time; live audio is available in the Investors section at www.908devices.com and will be archived for replay within 24 hours.